logo-loader
HealthPharma & Biotech
MaxCyte

MaxCyte launches latest iteration of its Flow Electroporation cell editing technology

Flow Electroporation is used in gene editing and allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance

expert machine maxcyte
ExPERT has been designed to improve the user experience

MaxCyte Inc (LON:MXCT) has launched an updated version of its Flow Electroporation cellular editing technology.

Flow Electroporation is used in gene editing and allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance.

LOOK: Take a look at ExPERT’s new features

This latest generation of tools, called ExPERT, boasts new updated software, a touchscreen interface and other features that MaxCyte says represent a “significant improvement” to the user experience.

The combination of the new instruments, together with the launch of a new range of processing assemblies, will allow customers to use a single technology from early research through to clinical and commercial use.

“We are proud to announce the launch of our next-generation ExPERT brand of instruments,” said chief executive and president Doug Doerfler.

Executive vice president of global commercial operations, Brad Calvin, added: “The ExPERT instrument family is the result of extensive customer research into feature design, functionality and performance that are considered critical to enabling the next generation of cellular therapies.

“Creating cellular editing platforms standardized on a single, scalable, high performance technology can assist the industry in accelerating timelines, reducing costs and achieving milestones critical to the translation of this promising new generation of cellular therapies.”

Quick facts: MaxCyte

Price: £1.20

Market: AIM
Market Cap: £68.89 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte named herein, including the promotion by the Company of MaxCyte in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read